CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.
“Looking back on my 25 years in academic medical research, I can’t think of a single learning experience that equipped me for the world of entrepreneurship, running a public company, or interacting with the capital markets.”
Being the founder and CEO of SQZ Biotech is actually Armon Sharei’s first full-time job. He warns that although people often applaud entrepreneurship, lionize its leaders, and paint it as a glamorous adventure, that isn’t really what it’s like.
Can German, American, Chinese, and other companies worldwide work together to advance the mRNA revolution and possibly launch the new “pharmacy of the world?”
While there are many key aspects of a successful international collaboration across many time zones and great distance, in our experience — a collaboration between organizations based in the U.S. and Japan — there are a few essential elements.
Like an ocean liner changing course, the national discussion around “modern” healthcare has moved slowly away from volume toward health outcomes. As such, we in the industry need to be both innovators and advocates for change.
“I’m often asked what it takes to be a successful biotech CEO, and as one of the relatively few female CEOs in our industry, what it takes to break the proverbial glass ceiling.”
Identifying and acquiring medicines would be relatively facile; however, convincing investors that the medicines were valuable was going to be a real challenge.
There are some key points for biotech companies to consider as they begin to transform their business model to one that captures the business continuum more fully.
Partnerships between pharmaceutical companies and patient advocacy groups hold the key to closing the rare-disease treatment gap. Their mutual commitment to improving patient care is the foundation for collaborative innovation in rare-disease education and research.
A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.
The career path of Orchard Therapeutics’ CEO Mark Rothera provides insight into how the executive came to be a champion of rare disease drug development.
Mark Rothera spent the majority of his career working for U.S.-based biopharmas. So, when he had the opportunity to work in his home country and preferred therapeutic area, he pursued it relentlessly.
You might know Richard Pops is one of the longest tenured CEOs in biopharma, but here are six things perhaps you didn’t know about the chairman of Alkermes.
Rob Wright provides insight into the categories and shared attributes of superbosses, as derived from 10 years of research and more than 200 interviews by Sydney Finkelstein, #23 on the Thinker50 2017 rankings.
Rob Wright discusses the difference between collaboration and teamwork, and what companies and leaders should be focusing on.
